



Diagnostica Senese Società Benefit S.p.A.

www.diesse.it



PRESS RELEASE

DIESSE ANNOUNCES A STRATEGIC PARTNERSHIP WITH GRIFOLS TO DISTRIBUTE TESTS FOR BIOLOGICAL DRUG MONITORING IN ITALY

Siena, 1st August 2022 - DIESSE Diagnostica Senese has announced a strategic agreement with Grifols for the distribution of Grifols' Promonitor assays portfolio, either on ELISA microplates or as a point of care technology (POCT), in Italy.

Monitoring biological drugs and anti-drug-antibodies provides precious diagnostic information to customize the treatment in patients with chronic inflammatory diseases.

DIESSE and Grifols have been business partners for many years and both companies have a strategic collaboration to develop new technologies in the clinical-diagnostics area of biological drug monitoring. This partnership is expressed at a global level with the availability of Promonitor tests on CHORUS system as a mono-test, enriching the over 150 tests available in the analytic menu of the instrument.

This further collaboration in the Italian area rounds out the solutions for biological drug assays. Customers can now use **Promonitor kit on ELISA** microplate and **Promonitor Quick** kit with dedicated reader, an easy-to-use and rapid POCT that can be used also in the doctor's office because no laboratory equipment is needed.

"The fruitful collaboration with Grifols continues: it represents a strategic value and a constant commitment to offer quality and innovative technology," states Luigi Nava, Commercial Operations Director of DIESSE. "We can offer Italian customers the entire portfolio of available solutions: this is a renewed responsibility and a promise for a qualitative and professional service, to concretely support our will of partnership."

"Grifols is committed to providing advanced technology solutions such as our Promonitor diagnostic testing portfolio to ensure safe and high-quality biological drug monitoring for patients," says Guillermo Marco-Gardoqui, vice president, Diagnostic Operations, Grifols.

This agreement confirms our commitment in providing the highest quality for each test and for each diagnostic information, in order to detect and evaluate Immune System alterations.



Diagnostica Senese Società Benefit S.p.A.

www.diesse.it



DIESESE Diagnostica Senese Società Benefit S.p.A. is an Italian company which produces integrated and entirely in-house in-vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems mainly in the field of immunodiagnosics and automatic ESR measurement.

The company has a global presence in over 100 countries, has 3 production sites and 1 research center, where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, identifying DIESESE as an example of real "Diagnostics Evolution".

Press Office:

Federica Casiraghi – DIESESE Diagnostica Senese

Tel.+39 342 9511925 – federicacasiraghi@diesse.it

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. It develops, produces and markets innovative solutions and services sold in more than 110 countries. Grifols, with more than 23,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. For more information, please visit www.grifols.com.

Grifols

Media Press Office:

media@grifols.com

Tel. + 34 93 571 00 02